

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicants:** Jawed Asrar and Jean R. Pierre**Serial No:** 10/635,316**Art Unit:** 1714**Filed:** August 6, 2003**Examiner:** Szekely, Peter**For:** *PHA COMPOSITIONS AND METHODS FOR THEIR USE IN THE PRODUCTION OF PHA FILMS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE
PATENTING REJECTION OVER AN ISSUED PATENT**

Sir:

Petitioner, Metabolix, Inc., is the owner of the entire interest in the above-identified application and U.S. Patent No. 6,620,869, issued September 16, 2003, as evidenced by the accompanying Statements Under 37 C.F.R. § 3.73(b). Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,620,869, or any continuation thereof under 37 C.F.R. § 1.53(b). Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and U. S. Patent No. 6,620,869 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. The appropriate fee for filing of this Terminal Disclaimer is enclosed.

11/03/2005 CNGUYEN 00000025 503129 10635316

01 FC:1814 130.00 DA

(45061637.1)
45061637-00055

1


MOBT 140 CON(2)
077832/55

U.S.S.N. 10/635,316
Filed: August 6, 2003
**TERMINAL DISCLAIMER TO OBLVATE A
DOUBLE PATENTING REJECTION
OVER AN ISSUED PATENT**

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154-156 and 173 of U. S. Patent No. 6,620,869, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that the granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned (whose title is supplied below) is empowered to act on behalf of Metabolix, Inc.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

By: 
Name: Patrea L. Pabst, Reg. No. 31,284
Title: Attorney of Record
Date: November 2, 2005

PTO/SB/96 (08-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Jawed Asrar and Jean R. PierreApplication No./Patent No.: 10/635,316 Filed/Issue Date: August 6, 2003Entitled: PHA COMPOSITIONS AND METHODS FOR THEIR USE IN THE PRODUCTION OF PHA FILMSMetabolix, Inc. a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
- OR USSN 10/635,316 is a CON of USSN 09/845,578, now US Patent No. 6,620,869
- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Jawed Asrar and Jean R. Pier To: Monsanto Company
The document was recorded in the United States Patent and Trademark Office at
Reel 9615, Frame 0048, or for which a copy thereof is attached.

2. From: Monsanto Company To: Metabolix, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 013676, Frame 0568, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature Date
Patrea L. Pabst, Reg. No. 31,284 November 2, 2005

Printed or Typed Name Telephone Number

Attorney of Record

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SD/46 (08-00)

Approved for use through 10/31/2002. OMB 0881-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Jawed Asrar and Jean R. PierreApplication No./Patent No.: 09/845,578 /USPat 6,620,869 Filed/Issue Date: April 3, 2001 /Issued: 09/16/2003Entitled: PHA COMPOSITIONS AND METHODS FOR THEIR USE IN THE PRODUCTION OF PHA FILMSMetabolix Inc.corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. | An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR 09/845,578 is a CON of 09/122,147 filed on 07/24/98

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Jawed Asrar and Jean R. Pier To: Monsanto Company *

The document was recorded in the United States Patent and Trademark Office at
Reel 9615, Frame 0048, or for which a copy thereof is attached.

2. From: Monsanto Company To: Metabolix, Inc.

The document was recorded in the United States Patent and Trademark Office at
Reel 013676, Frame 0568, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

| | Additional documents in the chain of title are listed on a supplemental sheet.

| | Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

JANUARY 16 2003

Date

OLIVER P. PEOPLES

Typed or printed name

OL P. PEOPLES

Signature

VP R & D

Title

Duration Hour Statement: This form is estimated to take 0.2 hours to complete. Time may vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

077832/00055